|
More than 50 million people – 1 out of 3 eligible Americans – do not complete colorectal cancer screening because they find the current options unpleasant or inconvenient.
Thankfully, physicians in Connecticut are beginning to prescribe Shield, the first blood test approved by the FDA as a primary screening option for colorectal cancer. This offers patients who may delay or avoid traditional screening methods a simpler, less invasive option for screening.
Veterans - The Shield™ blood test is covered as an in-network benefit for patients receiving VA-authorized community care.
October is National Health Literacy Month, which is a great opportunity to emphasize the importance of understanding your health and making informed choices about preventive care, including screening for colon cancer. Knowing your options and discussing them with your doctor can help you select the screening method that’s best for you, including whether the new blood test might be suitable.
Early detection saves lives, and expanding access to screening methods is a positive step toward better health outcomes for everyone.
|
